Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 10/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.43 |
| ▸ | SLC6A5 | Q9Y345 | 3/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.41 |
| ▸ | AVPR1B | P47901 | 2/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.40 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.38 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.38 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.38 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.38 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.38 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.38 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.38 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.38 |
| ▸ | BMP1 | P13497 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1054754 | 0.91 | SLC6A9 (0.42) | SLC6A9KCNH2SLC6A5CYP3A4CYP2D6 | |
| SCHEMBL1052540 | 0.91 | SLC6A9 (0.46) | SLC6A9KCNH2SLC6A5CYP3A4CYP2D6 | |
| SCHEMBL1050366 | 0.90 | SLC6A9 (0.46) | SLC6A9KCNH2SLC6A5CYP3A4FFAR1 | |
| SCHEMBL1050127 | 0.90 | AVPR1B (0.45) | SLC6A9KCNH2SLC6A5CYP3A4FFAR1 | |
| SCHEMBL1053627 | 0.90 | SLC6A9 (0.49) | SLC6A9KCNH2SLC6A5CYP3A4CYP2D6 | |
| SCHEMBL4545293 | 0.90 | SLC6A9 (0.45) | SLC6A9KCNH2SLC6A5CYP3A4CYP2D6 | |
| SCHEMBL15116095 | 0.89 | SLC6A9 (0.41) | SLC6A9KCNH2SLC6A5CYP3A4AVPR1B | |
| SCHEMBL15116054 | 0.89 | SLC6A9 (0.42) | SLC6A9KCNH2SLC6A5CYP3A4CYP2D6 | |
| SCHEMBL2687195 | 0.89 | SLC6A9 (0.42) | SLC6A9KCNH2SLC6A5CYP3A4CYP2D6 | |
| SCHEMBL1048174 | 0.89 | SLC6A9 (0.46) | SLC6A9KCNH2SLC6A5CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2454240-A1 | GLYCINE TRANSPORTER INHIBITORS | Taisho Pharmaceutical Co., Ltd. (JP) | 2012-05-23 | — | — | EP | claimed |
| US-20120116095-A1 | GLYCINE TRANSPORTER INHIBITORS | TAISHO PHARMACEUTICAL C0., LTD. (JP) | 2012-05-10 | — | — | US | claimed |
| WO-2011007899-A1 | GLYCINE TRANSPORTER INHIBITORS | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-01-20 | — | — | WO | claimed |
| EP-2454240-A1 | GLYCINE TRANSPORTER INHIBITORS | Taisho Pharmaceutical Co., Ltd. (JP) | 2012-05-23 | — | — | EP | disclosed |
| US-20120116095-A1 | GLYCINE TRANSPORTER INHIBITORS | TAISHO PHARMACEUTICAL C0., LTD. (JP) | 2012-05-10 | — | — | US | disclosed |
| US-20120116095-A1 | GLYCINE TRANSPORTER INHIBITORS | TAISHO PHARMACEUTICAL C0., LTD. (JP) | 2012-05-10 | — | — | US | disclosed |
| US-20120116095-A1 | GLYCINE TRANSPORTER INHIBITORS | TAISHO PHARMACEUTICAL C0., LTD. (JP) | 2012-05-10 | — | — | US | disclosed |
| WO-2011007899-A1 | GLYCINE TRANSPORTER INHIBITORS | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120116095-A1 | GLYCINE TRANSPORTER INHIBITORS | SLC6A5, SLC1A2, SLC18A2 | SLC6A9 5/4885KCNH2 1410/4885SLC6A5 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.